The enzyme has become an important drug target for the discovery and development of anti-inflammatory or anti-tumor drugs because selective inhibition of COX-2 may not only avoid the major side effects associated with COX-1 inhibition but also retain all of the benefits of classical non-steroidal anti-inflammatory drugs [7,8]. This evidence concerns the gene PTGS2 and neoplasm.